Abstract:Our findings provide a novel and effective combination strategy for increasing potent anthelmintic agent avermectin B1a production by enhancing supplies of both acyl‐CoA starter and extender units. We achieved significant increase of B1a titer in Streptomyces avermitilis WT and industrial strains by heterologous expression of assembled loading module‐extension module 7‐TE domain of meilingmycin polyketide synthase, inhibition of key nodes in FA synthesis and TCA cycle pathways using CRISPRi, and co‐overexpression of β‐oxidation pathway genes fadD and fadAB for increasing levels of 2‐methylbutyryl‐CoA, malonyl‐CoA, and methylmalonyl‐CoA precursors. Such precursor supply strategies can be readily adapted for overproduction of other polyketides. Avermectins (AVEs), a family of macrocyclic polyketides produced by Streptomyces avermitilis, have eight components, among which B1a is noted for its strong insecticidal activity. Biosynthesis of AVE "a" components requires 2‐methylbutyryl‐CoA (MBCoA) as starter unit, and malonyl‐CoA (MalCoA) and methylmalonyl‐CoA (MMCoA) as extender units. We describe here a novel strategy for increasing B1a production by enhancing acyl‐CoA precursor supply. First, we engineered meilingmycin (MEI) polyketide synthase (PKS) for increasing MBCoA precursor supply. The loading module (using acetyl‐CoA as substrate), extension module 7 (using MMCoA as substrate) and TE domain of MEI PKS were assembled to produce 2‐methylbutyrate, providing the starter unit for B1a production. Heterologous expression of the newly designed PKS (termed Mei‐PKS) in S. avermitilis wild‐type (WT) strain increased MBCoA level, leading to B1a titer 262.2 μg/mL – 4.36‐fold higher than WT value (48.9 μg/mL). Next, we separately inhibited three key nodes in essential pathways using CRISPRi to increase MalCoA and MMCoA levels in WT. The resulting strains all showed increased B1a titer. Combined inhibition of these key nodes in Mei‐PKS expression strain increased B1a titer to 341.9 μg/mL. Overexpression of fatty acid β‐oxidation pathway genes in the strain further increased B1a titer to 452.8 μg/mL – 8.25‐fold higher than WT value. Finally, we applied our precursor supply strategies to high‐yield industrial strain A229. The strategies, in combination, led to B1a titer 8836.4 μg/mL – 37.8% higher than parental A229 value. These findings provide an effective combination strategy for increasing AVE B1a production in WT and industrial S. avermitilis strains, and our precursor supply strategies can be readily adapted for overproduction of other polyketides.

Synthetic Biology of Avermectin for Production Improvement and Structure Diversification

Interrogation of Streptomyces avermitilis for efficient production of avermectins.

Research progress of avermectin: A minireview based on the structural derivatization of avermectin

Natural Products from Bacillus Subtilis with Antimicrobial Properties

Learn from microbial intelligence for avermectins overproduction.

Engineering of Avermectin Biosynthetic Genes to Improve Production of Ivermectin in Streptomyces Avermitilis

Advances in Technology for the Production of Avermectins

Direct Proteomic Mapping of Streptomyces Avermitilis Wild and Industrial Strain and Insights into Avermectin Production

Designed biosynthesis of 25-methyl and 25-ethyl ivermectin with enhanced insecticidal activity by domain swap of avermectin polyketide synthase

Overexpression of the ABC Transporter AvtAB Increases Avermectin Production in Streptomyces Avermitilis.

Heterologous Expression of Avermectins Biosynthetic Gene Cluster by Construction of a Bacterial Artificial Chromosome Library of the Producers

Enhancement of acyl‐CoA precursor supply for increased avermectin B1a production by engineering meilingmycin polyketide synthase and key primary metabolic pathway genes

Reverse Biological Engineering Of Hrdb To Enhance The Production Of Avermectins In An Industrial Strain Of Streptomyces Avermitilis

[Enhanced avermectin production by rational feeding strategies based on comparative metabolomics].

Avermectin B1a production in Streptomyces avermitilis is enhanced by engineering aveC and precursor supply genes

Enhancement and Selective Production of Avermectin B by Recombinants of Streptomyces Avermitilis Via Intraspecific Protoplast Fusion

Increasing Avermectin Production in Streptomyces avermitilis by Manipulating the Expression of a Novel TetR-Family Regulator and Its Target Gene Product

A Novel TetR Family Transcriptional Regulator, SAV576, Negatively Controls Avermectin Biosynthesis in Streptomyces Avermitilis

Construction of Ivermectin Producer by Domain Swaps of Avermectin Polyketide Synthase in Streptomyces Avermitilis

Construction of a Doramectin Producer Mutant from an Avermectin-Overproducing Industrial Strain of Streptomyces Avermitilis

High Value Utilization of an Avermectin Fermentation Byproduct: Novel B2a Derivatives As Pesticide Candidates.